Founder Directory
Built by Keitoto
Founders3
Known for these resultsRole33%Role is parsed from founder titles in yc.db. Known for 33% of these rows — the rest have no title at all, mostly 2019–2023. Those rows stay in the result and are counted as Unknown, never as No.Bio100%Bio coverage: 100% of these founders have a bio on their YC profile. Every bio-derived facet (ex-company, school, credentials, discipline) is Unknown for the rest.Ex-company0%Ex-company is matched from bios with employment context (ex-, formerly, worked at). 0% of these rows have at least one match.School100%School is matched from bios, case-sensitive for acronyms. 100% of these rows have at least one match.
- Jeff LiuFounder/CEO · FinalDoseX26Healthcare · London
- Li-Yao HuangFounder · FinalDoseX26Healthcare · London
- Steven LinFounder · FinalDoseX26Healthcare · London
FOUNDERROLEBATCHINDUSTRYLOCATIONTEAMX_url
Jeff LiuFinalDoseFounder/CEOSpring 2026HealthcareLondon, United Kingdom5—Li-Yao HuangFinalDoseFounderSpring 2026HealthcareLondon, United Kingdom5—Steven LinFinalDoseFounderSpring 2026HealthcareLondon, United Kingdom5—
Showing 1–3 of 3 founders
Steven Lin
Founder·FinalDose
PRIMARY INFO
RoleFounder· not in title
Team size5
BatchSpring 2026
LocationLondon, United Kingdom
Company statusActive
StageEarly
BIO
Cofounder and CTO at FinalDose (YC P26). Oxford PhD in Computational Biology with Wellcome Trust full scholarship. Previously Data Lead at Gutsee Biotech. Developed novel machine learning method to use coevolution biology to identify genetic targets that convey drug resistance in viruses. During SARS-CoV-2 pandemic, led UK biobank analysis of human genetics susceptibility for infections
Ex-company, school and discipline below are derived from this bio. Nothing is inferred when the bio is missing.
BACKGROUND
CredentialsPhD
DisciplineResearcherKeyword match from the bio text, not a classifier.
TRACK RECORD
First YC company on record
COMPANY CONTEXT
FinalDoseProgrammable DNA drug destroying all cancers, unlocking 80% of targets
